Antonio Calles, Medical Oncologist at Hospital General Universitario Gregorio Marañón and faculty member of the Lung and Other Thoracic Tumours faculty group of the ESMO, shared on X:
“Specially proud of this study in which we have actively participated and to see the outstanding efficacy of a 4th generation ROS1 TKI in 1L NSCLC presented by Alexander Drilon, Nuvalent, IASLC.
ORR 94% IC-ORR 100% DoR and PFS NR.
Low rates of toxicities and discontinuation.”
You can also read:
Advancing Innovation in Small Cell Lung Cancer at WCLC 2026 – Amgen
